Active Biotech to Present at the UBS Global Life Sciences Conference

(Thomson Reuters ONE) - Lund, Sweden, September 17, 2009 - Active Biotech (NASDAQ OMX Nordic:ACTI) is scheduled to present at the UBS Global Life SciencesConference held September 21-23, 2009 at the Grand Hyatt, GrandCentral in New York City, US. During the presentation, an updateregarding Active Biotech's development programs will be provided.The presentation will include the Phase III projects laquinimod, anovel oral immunomodulatory drug for the treatment of multiplesclerosis, which is licensed to Teva Pharmaceutical Industries Ltdand ANYARA, Active Biotech's novel concept for tumor therapy in aPhase III study for renal cell cancer. Also, the prostate cancerproject TASQ, the SLE project 57-57 and the pre-clinical ISI projectwill be presented.The audio and slide presentation will be webcasted live and can beaccessed via the Active Biotech web site. To access the live andreplay presentations please go to - www.activebiotech.com.The presentation will take place on September 22, at 2:00 pm USEastern Time / 20:00 Central European Time.About Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnologycompany with focus on autoimmune/inflammatory diseases and cancer.Projects in pivotal phase are laquinimod, an orally administeredsmall molecule with unique immunomodulatory properties for thetreatment of multiple sclerosis, as well as ANYARA for use in cancertargeted therapy, primarily of renal cancer. Further key projects inclinical development comprise the three orally administered compoundsTASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for more information.Active Biotech is required under the Securities Markets Act to makethe information in this press release public. The information wassubmitted for publication at 2:00 pm CET on September 17, 2009.Contacts:Active Biotech ABGöran Forsberg, VP Investor Relations & BusinessDevelopmentP.O. Box 724, SE-220 07 Lund, SwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 11 00This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 17.09.2009 - 14:01 Uhr
Sprache: Deutsch
News-ID 5926
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 284 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech to Present at the UBS Global Life Sciences Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech